{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-226878","form_type":"8-K","ticker":"MGX","cik":"0001785279","company_name":"Metagenomi Therapeutics, Inc.","filed_at":"2025-10-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.449805+00:00","generated_at":"2026-05-17T05:06:35.245561+00:00","sec_items":["1.01","1.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Metagenomi enters LNP license with Acuitas, terminates Affini-T TCR deal","bullets":["Non-exclusive Acuitas license for LNP technology; low-seven-figure annual maintenance fee until first Phase 1 dosing.","Milestone payments low to mid seven figures for regulatory/commercial events; royalties low mid-single digit % of net sales.","Terminated Affini-T agreement effective Sept 30, 2025 due to Affini-T's assignment for benefit of creditors.","Metagenomi regains full control over IP and rights to develop TCR-based therapeutics previously licensed to Affini-T.","No future payments expected from Affini-T under terminated agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-226878","json":"https://secwatch.observer/filing/0001193125-25-226878.json","markdown":"https://secwatch.observer/filing/0001193125-25-226878.md","text":"https://secwatch.observer/filing/0001193125-25-226878.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785279/000119312525226878/0001193125-25-226878-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785279/000119312525226878/mgx-20250929.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:06:35.245561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}